Video

Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Delvys Rodriguez-Abreu, MD, medical oncologist at Hospital Universitario Insular de Gran Canaria in Gran Canaria, Spain, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non—small cell lung cancer (NSCLC).

In the phase 3 trial, the median time from randomization to data cutoff was 31.0 months, Rodriguez-Abreu says. Patients were randomized 2:1 to receive 35 cycles of pembrolizumab (Keytruda) at 200 mg every 3 weeks or placebo every 3 weeks plus 4 cycles of pemetrexed and carboplatin/cisplatin followed by maintenance pembrolizumab. Of the 616 patients with NSCLC enrolled on the study, 410 received pembrolizumab plus chemotherapy and 206 patients received placebo plus chemotherapy.

At the time of the data cutoff, which was May 20, 2019, 17 patients in the pembrolizumab-plus-chemotherapy arm were still receiving initially assigned treatment compared with only 1 patient in the placebo-plus-chemotherapy arm. A total of 84 patients, concludes Rodriguez-Abreu.

Related Videos
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc